Asuragen launches new in-vitro diagnostic device

Based upon patented technology, RNARetain is labeled for the collection, storage, and transport of clinical human cellular and solid tissue specimens and stabilization of intracellular RNA within these specimens for subsequent extraction and molecular analysis.

According to the company, RNARetain infiltrates tissues and cells, precipitating nucleic acids and proteins in situ providing powerful protection of cellular RNA from both intracellular and extracellular ribonucleases, which would otherwise rapidly degrade the RNA in the specimen.

Matt Winkler, chief scientific officer and CEO of Asuragen, said: “RNARetain will become a valuable tool in molecular diagnostics and future personalized medicine applications by allowing shipment of fresh tumor biopsies at ambient temperature, thus greatly facilitating the logistical process of sample handling.”